Botulism clinical trials
The registry lists 20 studies for Botulism across 4 countries. 3 are recruiting or about to start. 18 of them are mainly about Botulism (how this is decided). Per ClinicalTrials.gov, last updated 2026-07-30.
Get an email when these change. Save the Botulism studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Institute of Allergy and Infectious Diseases (NIAID) (3) · California Department of Public Health (3) · DynPort Vaccine Company LLC, A GDIT Company (2) · Emergent BioSolutions (2) · Rajavithi Hospital (2) · Wake Forest University Health Sciences (1) · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation (1) · National Taiwan University Hospital (1)
What is being tested here
Drugs under test in Botulism studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Botulinum Toxins | 1 | 1 | 1 |
| Recombinant botulinum vaccine A/B | 0 | 1 | 4 |
| Amifampridine | 0 | 1 | 2 |
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
Who these studies take
Of the 1 Botulism studies recruiting now, 1 (100%) set no upper age limit and 0 (0%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 1 (100%) | 1 (100%) |
| 30 | 1 (100%) | 1 (100%) |
| 40 | 1 (100%) | 1 (100%) |
| 50 | 1 (100%) | 1 (100%) |
| 65 | 1 (100%) | 1 (100%) |
| 75 | 1 (100%) | 1 (100%) |
| 85 | 1 (100%) | 1 (100%) |
Across all 20 studies, recruiting or not: 60% stop at 75 or younger and 45% at 65; 30% take children; 0% are for women only and 0% for men only; 50% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 20 of 20. search them.
- BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric PatientsEnrolling by invitationNCT02051062Phase 4
- Injection of Botulinum Toxin for Thumb Carpometacarpal ArthritisRecruitingNCT05990881Phase 31 country
- Study of the Drug B11-FC (Botulism Treatment)Not yet recruitingNCT06580236Phase 1/2
- Tolerability and Immunogenicity of a Single 40-ug Dose of rBV A/B for the Production of BabyBIG®CompletedNCT06112834Phase 21 country
- Retrospective Epidemiological Study on Botulism in Intensive Care Units in FranceCompletedNCT036589021 country
- Pilot Study on the Usefulness of 3,4-diaminopyridine in the Treatment of BotulismCompletedNCT01441557Phase 2/31 country
- Effect of Amifampridine on Neuromuscular Transmission in Patients Treated With OnabotulinumtoxinACompletedNCT05769478Phase 11 country
- Study to Evaluate Safety and PK of a Single IM Dose of G03-52-01 vs Placebo in Adult SubjectsCompletedNCT04171115Phase 11 country
- BT-010 Registry for the Evaluation of Safety and Clinical Outcomes in Patients Treated With Botulinum AntitoxinCompletedNCT02055183
- A Study to Evaluate the Safety and Pharmacokinetics of NTM-1633 vs Placebo Administered Intravenously in Healthy AdultsCompletedNCT03603665Phase 11 country
- Tolerability and Immunogenicity of rBV A/B for the Production of BabyBIG®CompletedNCT03676634Phase 21 country
- Using Shear Wave Ultrasound Elastography for Follow up After Anti-spastic Intervention Among Stroke PatientsStatus unknownNCT045507931 country
- Phase 3, Randomized, Safety, Lot Consistency and Clinical Benefit Study of Recombinant Botulinum Vaccine A/BWithdrawnNCT01940315Phase 3
- Phase I, Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of NTM-1632CompletedNCT02779140Phase 11 country
- Safety, Tolerability, and Immunogenicity Study of Investigational Recombinant Botulinum Vaccine A/B (rBV A/B) in Volunteers Previously Immunized With Investigational Pentavalent Botulinum ToxoidCompletedNCT01701999Phase 21 country
- Study of Human Botulism Immunoglobulin in Infants With BotulismCompletedNCT00004401Not applicable1 country
- Phase 1 PK Study of XOMA 3ABCompletedNCT01357213Phase 11 country
- Double Blind, Safety and Immunogenicity Study of Recombinant Botulinum Vaccine A/BCompletedNCT00764634Phase 21 country
- Treatment of Survivors After Botulism OutbreakCompletedNCT003140801 country
- Botulism Outbreak in Thailand (Episode II)CompletedNCT003484261 country